Vaknin Rachel 4
4 · Microbot Medical Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Microbot Medical (MBOT) CFO Vaknin Receives 105,000-Share Award
What Happened
Rachel Vaknin, Chief Financial Officer of Microbot Medical, received a grant of derivative awards covering 105,000 shares on February 18, 2026. The Form 4 reports the acquisition as an award/ grant (code A) with a reported price of $0.00 at grant — this is a stock award/option-style grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely; Form 4s are generally due within two business days).
- Security: derivative award covering 105,000 shares (reported price $0.00).
- Shares owned after transaction: not specified in the filing.
- Plan: Issuer’s 2020 Omnibus Performance Award Plan, as amended.
- Footnote: Vesting schedule — 25% vests on August 18, 2026; the remaining 75% vests quarterly over the subsequent 30 months, subject to acceleration or forfeiture under the Plan.
Context
This was a grant of equity-based awards (derivative instruments) rather than a purchase of shares. Such grants are common for executive compensation and do not by themselves indicate buying or selling sentiment; vesting conditions and future exercise/sale behavior determine potential insider exposure. The award’s vesting schedule includes time-based installments and is subject to plan terms.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-18+105,000→ 105,000 totalExercise: $2.10Exp: 2036-02-18→ Common Stock, par value $0.01 per share (105,000 underlying)
Footnotes (1)
- [F1]The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.